Top US Growth Stocks With High Insider Ownership

In This Article:

As the S&P 500 and Nasdaq continue their upward momentum, driven by a tech rally and positive inflation data, investors are increasingly looking for growth opportunities in the U.S. market. One key indicator of a potentially strong investment is high insider ownership, which often signals confidence from those closest to the company.

Top 10 Growth Companies With High Insider Ownership In The United States

Name

Insider Ownership

Earnings Growth

Atour Lifestyle Holdings (NasdaqGS:ATAT)

26%

21.6%

PDD Holdings (NasdaqGS:PDD)

32.1%

21.8%

GigaCloud Technology (NasdaqGM:GCT)

25.7%

24.1%

Hims & Hers Health (NYSE:HIMS)

13.7%

40.9%

Super Micro Computer (NasdaqGS:SMCI)

14.3%

31.3%

Credo Technology Group Holding (NasdaqGS:CRDO)

14.4%

60.9%

Clene (NasdaqCM:CLNN)

22.3%

62.6%

EHang Holdings (NasdaqGM:EH)

32.8%

75%

Carlyle Group (NasdaqGS:CG)

29.5%

22.8%

BBB Foods (NYSE:TBBB)

22.9%

70.7%

Click here to see the full list of 175 stocks from our Fast Growing US Companies With High Insider Ownership screener.

Let's take a closer look at a couple of our picks from the screened companies.

AvePoint

Simply Wall St Growth Rating: ★★★★☆☆

Overview: AvePoint, Inc. offers a cloud-native data management software platform across North America, Europe, the Middle East, Africa, and Asia Pacific with a market cap of $1.96 billion.

Operations: The company's revenue segment comprises $299.88 million from Software & Programming.

Insider Ownership: 36.9%

Revenue Growth Forecast: 17% p.a.

AvePoint, Inc. has demonstrated significant revenue growth, reporting US$77.96 million for Q2 2024, up from US$64.87 million a year ago, with a net loss narrowing to US$14.53 million for the first half of 2024 compared to US$21.78 million previously. Despite being dropped from several Russell indices in July 2024, AvePoint's forecasted annual profit growth is above market average and insiders have shown more buying than selling activity recently.

NasdaqGS:AVPT Ownership Breakdown as at Aug 2024

Krystal Biotech

Simply Wall St Growth Rating: ★★★★★☆

Overview: Krystal Biotech, Inc. is a commercial-stage biotechnology company that discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States, with a market cap of $5.30 billion.

Operations: Krystal Biotech focuses on the discovery, development, and commercialization of genetic medicines for rare diseases in the United States.

Insider Ownership: 10.7%

Revenue Growth Forecast: 32.9% p.a.